Octapharma AG - Virus & Prion Validation Frankfurt 
EN: Navigation mit Access Keys
- [Alt + 0] - Startseite
- [Alt + 1] - Navigation
- [Alt + 2] - Inhalt
- [Alt + 3] - Kontakt
- [Alt + 4] - Sitemap
- [Alt + 5] - Suche
Develops nonvel Plasma-derived Therapeutic Protein Products
EN: Hauptnavigation
Virus & Prion Validation Frankfurt
Efforts at the Virus & Prion Validation unit support Octapharma’s commitment to safe protein products derived from human plasma and human cell lines.
The state-of-the-art Frankfurt facility is certified to Good Laboratory Practice (GLP) for the provision of comprehensive GLP-compliant virus and prion validation studies with the highest level of quality and regulatory compliance.
Work includes:
- Research and validation of virus and other pathogen inactivation steps in novel processes
- Re-validation and robustness studies of established process steps in a laboratory scale in the presence of viruses including HIV and WNV
- Research on emerging new viruses
- Providing a complete portfolio of human plasma-derivates to meet both current and future therapeutic needs


